Investors
& Media
A clinical-stage gene therapy company striving to halt or reverse
disease with a single dose.
We are AVROBIO
Our vision is to bring personalized gene therapy to the world. We aim to prevent, halt or reverse disease throughout the body with a single dose of gene therapy designed to drive durable expression of functional protein, even in hard-to-reach tissues and organs including the brain, muscle and bone. Our ex vivo lentiviral gene therapy pipeline includes clinical programs in Fabry disease, Gaucher disease type 1 and cystinosis, as well as preclinical programs in Hunter syndrome, Gaucher disease type 3 and Pompe disease. AVROBIO is powered by its industry leading plato® gene therapy platform, our foundation designed to deliver gene therapy worldwide. We are headquartered in Cambridge, Mass., with an office in Toronto, Ontario.
Sign up for email alerts
|
Data Provided by Refinitiv. Minimum 15 minutes delayed.
AVROBIO at the Morgan Stanley Virtual Healthcare Corporate Access Day
Chris Brinzey
Westwicke Partners for AVROBIO
Phone: 339-970-2843
Email: chris.brinzey@westwicke.com